Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions | |
| pubmed:issue |
4
|
| pubmed:dateCreated |
1992-11-4
|
| pubmed:abstractText |
From 1964 to 1989, bone metastases were found in 28 of 600 patients operated on for differentiated thyroid carcinoma. Bone metastasis was the presenting symptom in 15 (54%) patients, was detected from the initial symptom in 4 (14.5%) patients, and occurred subsequently in 9 (32%) patients, with an average lag time of 4.5 years after surgical treatment. Pathological pattern of the thyroid cancer was follicular in 26 (93%) patients and papillary in 2 (7%) patients. Bone metastatic involvement was multiple in 21 (75%) patients and associated with other synchronous or metachronous distant metastases in 13 (46%) patients, especially in the lung (10 patients) or the brain (3 patients). The primary treatment of thyroid carcinoma was total thyroidectomy in all 28 patients, with additional modified neck dissection in 8 patients. All 15 patients presenting with symptoms had bone metastases demonstrated by x-ray studies. Six of the bone metastases only took up radioactive iodine 6 weeks after total thyroidectomy, as did 2 of 4 bone metastases detected at initial observation and 4 of 9 metachronous bone metastases. All 12 patients with functioning bone metastases were given radioactive iodine therapy; 4 of the metastases were surgically resected. Only 2 patients with bone metastases showed a complete response after an ablative dose of I-131; none of the metastases had been demonstrated by x-ray studies. Radioactive iodine therapy cures no more than 17% of patients with bone metastases taking up radioactive iodine and 7% of all patients with bone metastases. All patients cured of bone metastases were given radioactive iodine, either alone, or combined with other treatment.(ABSTRACT TRUNCATED AT 250 WORDS)
|
| pubmed:language |
eng
|
| pubmed:journal | |
| pubmed:citationSubset |
IM
|
| pubmed:chemical | |
| pubmed:status |
MEDLINE
|
| pubmed:issn |
0364-2313
|
| pubmed:author | |
| pubmed:issnType |
Print
|
| pubmed:volume |
16
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
N
|
| pubmed:pagination |
640-5; discussion 645-6
|
| pubmed:dateRevised |
2004-11-17
|
| pubmed:meshHeading |
pubmed-meshheading:1384244-Adenocarcinoma,
pubmed-meshheading:1384244-Adolescent,
pubmed-meshheading:1384244-Adult,
pubmed-meshheading:1384244-Aged,
pubmed-meshheading:1384244-Bone Neoplasms,
pubmed-meshheading:1384244-Carcinoma, Papillary,
pubmed-meshheading:1384244-Combined Modality Therapy,
pubmed-meshheading:1384244-Female,
pubmed-meshheading:1384244-Follow-Up Studies,
pubmed-meshheading:1384244-Humans,
pubmed-meshheading:1384244-Iodine Radioisotopes,
pubmed-meshheading:1384244-Male,
pubmed-meshheading:1384244-Middle Aged,
pubmed-meshheading:1384244-Palliative Care,
pubmed-meshheading:1384244-Postoperative Care,
pubmed-meshheading:1384244-Retrospective Studies,
pubmed-meshheading:1384244-Thyroid Neoplasms,
pubmed-meshheading:1384244-Thyroidectomy,
pubmed-meshheading:1384244-Treatment Outcome
|
| pubmed:articleTitle |
Is it still worthwhile to treat bone metastases from differentiated thyroid carcinoma with radioactive iodine?
|
| pubmed:affiliation |
Department of General and Endocrine Surgery, CHUP Lille, France.
|
| pubmed:publicationType |
Journal Article
|